In 116 adults with AML or MDS having stem cell transplant, spreading busulfan over 3 weeks (arm B) vs 2 weeks (arm A), with fludarabine and cladribine, did not significantly improve 3-year PFS (61.3% vs 48.7%; P=.19) but cut grade ≥3 toxicity (73.7% vs 93.2%).
RCTn = 116
Popat et al. Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes